| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
31,804,000 |
| Market
Cap: |
612.86(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$13.85 - $26.47 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 609 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile AnaptysBio is a clinical stage biotechnology company developing immunology therapeutic product candidates focused on immune control mechanisms applicable to inflammation and immuno-oncology indications. Co.'s wholly-owned antibody programs include: imsidolimab, which inhibits the interleukin-36 receptor and is being developed for the treatment of multiple dermatological inflammatory diseases; rosnilimab, which is an anti-PD-1 agonist antibody program designed to augment PD-1 signaling via rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, which is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
668,237 |
| Total Buy Value |
$0 |
$0 |
$0 |
$14,453,966 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
157,005 |
171,792 |
185,897 |
858,303 |
| Total Sell Value |
$3,586,878 |
$3,902,662 |
$4,176,146 |
$18,726,680 |
| Total People Sold |
3 |
4 |
4 |
5 |
| Total Sell Transactions |
4 |
9 |
14 |
18 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Faga Daniel |
CEO |
• • – |
2024-03-26 |
4 |
D |
$21.60 |
$7,504,726 |
D/D |
(347,441) |
401,646 |
|
- |
|
| Faga Daniel |
CEO |
• • – |
2024-03-25 |
4 |
S |
$21.42 |
$64,268 |
D/D |
(3,000) |
749,087 |
|
9% |
|
| Faga Daniel |
CEO |
• • – |
2024-03-22 |
4 |
S |
$22.78 |
$3,325,185 |
D/D |
(145,940) |
752,087 |
|
11% |
|
| Loumeau Eric J |
CHIEF LEGAL OFFICER |
• – – |
2024-02-16 |
4 |
AS |
$25.00 |
$125,000 |
D/D |
(5,000) |
3,240 |
|
-18% |
|
| Loumeau Eric J |
CHIEF LEGAL OFFICER |
• – – |
2024-02-16 |
4 |
OE |
$14.02 |
$70,100 |
D/D |
5,000 |
8,240 |
|
- |
|
| Mulroy Dennis |
CHIEF FINANCIAL OFFICER |
• – – |
2024-01-30 |
4 |
AS |
$23.63 |
$72,425 |
D/D |
(3,065) |
964 |
|
-17% |
|
| Loumeau Eric J |
Chief Legal Officer |
• – – |
2024-01-08 |
4 |
S |
$21.81 |
$50,272 |
D/D |
(2,305) |
3,240 |
|
15% |
|
| Lizzul Paul F. |
Chief Medical Officer |
• – – |
2024-01-08 |
4 |
S |
$21.81 |
$55,703 |
D/D |
(2,554) |
10,118 |
|
15% |
|
| Faga Daniel |
CEO |
• • – |
2024-01-08 |
4 |
S |
$21.81 |
$149,747 |
D/D |
(6,866) |
898,027 |
|
15% |
|
| Mulroy Dennis |
Chief Financial Officer |
• – – |
2024-01-08 |
4 |
S |
$21.81 |
$47,546 |
D/D |
(2,180) |
4,029 |
|
15% |
|
| Loumeau Eric J |
Chief Legal Officer |
• – – |
2024-01-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,545 |
5,545 |
|
- |
|
| Lizzul Paul F. |
Chief Medical Officer |
• – – |
2024-01-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,145 |
12,672 |
|
- |
|
| Faga Daniel |
CEO |
• • – |
2024-01-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,850 |
904,893 |
|
- |
|
| Mulroy Dennis |
Chief Financial Officer |
• – – |
2024-01-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,245 |
6,209 |
|
- |
|
| Loumeau Eric J |
Chief Legal Officer |
• – – |
2023-11-22 |
4 |
AS |
$14.19 |
$12,516 |
D/D |
(882) |
0 |
|
50% |
|
| Loumeau Eric J |
Chief Legal Officer |
• – – |
2023-09-18 |
4 |
AS |
$19.32 |
$75,232 |
D/D |
(3,895) |
882 |
|
23% |
|
| Mulroy Dennis |
Chief Financial Officer |
• – – |
2023-09-18 |
4 |
AS |
$19.32 |
$75,237 |
D/D |
(3,895) |
964 |
|
23% |
|
| Loumeau Eric J |
Chief Legal Officer |
• – – |
2023-09-14 |
4 |
AS |
$19.48 |
$41,005 |
D/D |
(2,105) |
4,777 |
|
20% |
|
| Loumeau Eric J |
Chief Legal Officer |
• – – |
2023-09-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,000 |
6,882 |
|
- |
|
| Mulroy Dennis |
Chief Financial Officer |
• – – |
2023-09-14 |
4 |
AS |
$19.48 |
$41,005 |
D/D |
(2,105) |
4,859 |
|
20% |
|
| Mulroy Dennis |
Chief Financial Officer |
• – – |
2023-09-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,000 |
6,964 |
|
- |
|
| Lizzul Paul F. |
Chief Medical Officer |
• – – |
2023-09-14 |
4 |
S |
$19.48 |
$41,005 |
D/D |
(2,105) |
6,527 |
|
-20% |
|
| Lizzul Paul F. |
Chief Medical Officer |
• – – |
2023-09-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,000 |
8,632 |
|
- |
|
| Loumeau Eric J |
COO, General Counsel |
• – – |
2022-08-08 |
4 |
AS |
$25.00 |
$13,075 |
D/D |
(523) |
0 |
|
9% |
|
| Loumeau Eric J |
COO, General Counsel |
• – – |
2022-06-08 |
4 |
AS |
$24.00 |
$60,000 |
D/D |
(2,500) |
523 |
|
14% |
|
130 Records found
|
|
Page 1 of 6 |
|
|
0.09 (0.47%) 
